首页/数据集/TABLE 2 from Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer

TABLE 2 from Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer

Figshare2023-08-28 更新2026-04-28 收录

胰腺癌一线化疗

客观缓解率评估

数据链接：

https://figshare.com/articles/dataset/TABLE_2_from_Gemcitabine_Docetaxel_Capecitabine_Cisplatin_Irinotecan_as_First-line_Treatment_for_Metastatic_Pancreatic_Cancer/24042998 数据链接链接失效反馈

官方服务：

资源简介：

Objective responses in the expansion cohort

应用场景：

创建时间：

2023-08-28

结直肠癌肝转移风险

客观缓解率评估

Primary objectives: To assess the objective response rate (ORR) over the entire treatment period when panitumumab is administered in combination with XELOX chemotherapy as 1st-line therapy in patients

NIAID Data Ecosystem90

A phase II study of alternate-day administration of S-1, oral leucovorin, oxaliplatin, and bevacizumab combination as first-line treatment in patients with metastatic colorectal cancer.

结直肠癌二线治疗研究

客观缓解率评估

Interventions: S-1 80-120 (mg/day) Monday, Wednesday, Friday, Sunday Leucovorin 50 (mg/day) Monday, Wednesday, Friday, Sunday Oxaliplatin 85 (mg/m2) day1 Bevacizumab 5 (mg/kg) day 1 every 2 weeks Prim

NIAID Data Ecosystem50

A PHASE 2, MULTICENTER, OPEN-LABEL STUDY OF DS-8201A IN SUBJECTS WITH HER2-EXPRESSING ADVANCED COLORECTAL CANCER[DESTINY-CRC01]

HER2阳性结直肠癌临床试验

客观缓解率评估

Primary objectives: To determine the objective response rate (ORR) of DS-8201a in HER2 - positive advanced metastatic colorectal cancer patients. (Cohort A). Primary endpoints: Objective response rate

NIAID Data Ecosystem30

Bevacizumab + Folfox4 or Xelox2 as first- line treatment in colorectal cancer. Randomized phase II study.

结直肠癌一线化疗

客观缓解率评估

Primary objectives: To estimate the effectiveness of the combination of Oxaliplatino and Capecitabine (XELOX-2) + bevacizumab measured in terms of objective response rate in non treaty advanced colore

NIAID Data Ecosystem50

First Line UFT, OXALIPLATIN and ERBITUX combination (TEGAFOX-E) in Elderly (≥ 70 years) metastatic colorectal patients: a Phase II ITMO study.

转移性结直肠癌临床试验

客观缓解率评估

Primary objectives: To assess the respons rate ORR (CR+PR)

NIAID Data Ecosystem40